Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine
Summary
- Anixa just released the first efficacy data for its triple-negative breast cancer vaccine candidate.
- Triple-negative breast cancer is the most aggressive and deadly form of breast cancer.
- The safety and efficacy data are promising and could allow any woman to be eligible to take the vaccine candidate.
- If successful, Anixa’s vaccine candidate would be a revolution in cancer care, and possibly a nice addition to a big pharma vaccine portfolio.
- The stock seems to have suffered a sell-the-news event, possibly related to a publication mishap.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of ANIX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.